Ic-MPGN
Clinical trials for Ic-MPGN explained in plain language.
Never miss a new study
Get alerted when new Ic-MPGN trials appear
Sign up with your email to follow new studies for Ic-MPGN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a single injection drug calm the immune attack on kidneys?
Disease control OngoingThis phase 2 trial tests an experimental drug called SGB-9768 in adults with three related kidney diseases: IgA nephropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis. These conditions occur when the immune system deposits proteins in…
Matched conditions: IC-MPGN
Phase 2 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Matched conditions: IC-MPGN
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control ApprovedThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Matched conditions: IC-MPGN
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC